




## COMMUNITY CONNECTION


Quarterly Newsletter  
May 2024



## Study Highlight: WF-1901 IMPACTS

We need  
24 enrollments

INTERNET-DELIVERED MANAGEMENT OF PAIN  
AMONG CANCER TREATMENT SURVIVORS  
**impacts**  
by June 30<sup>th</sup>



**As a final push to meet our target goal of 24 enrollments by June 30<sup>th</sup> we desperately need your help!**



**The successful achievement of this goal, if accomplished, would not only ensure the continuation of the study for another year, but also offer additional resources to eligible cancer patients and survivors who are currently dealing with pain.**

### **As a reminder: Brief eligibility criteria**

- Must have a documented diagnosis of invasive cancer that has been treated with either single modality therapy or any combination of surgery, radiation, and chemotherapy/drug therapy.
- May be either off all treatment OR actively receiving anticancer therapy in an adjuvant setting, maintenance setting, or for active cancer.
- Patients who are no longer receiving anticancer therapy must be **≤ 5 years since the completion of their anticancer therapy** (e.g., time since the last day of chemotherapy administration, time since last day of radiotherapy, etc.).
- Must have pain indicated by a score of **≥ 4 on PROMIS Pain Intensity** (1a) scale, using the Pain Eligibility Interview within the Screening Interview.
- Must have a score of **“Most Days”** or higher on the Graded Chronic Pain Scale Revised (Abbreviated) using the Pain Eligibility Interview within the Screening Interview.
- Patients do not have to be on analgesic medications of any kind in order to participate. If they are taking analgesics, **they must be on a stable analgesic regimen over a period of at least 14 days prior to enrollment.**
- **Must have pain of new onset or significantly exacerbated since the time of cancer diagnosis or initiation of cancer treatment.**

**As always, we greatly appreciate every contribution each site has made to the enrollment of WF-1901 IMPACTS thus far!**

**If you would like to learn more about IMPACTS, need refresher trainings, or are interested in knowing more about our Site-to-Site Mentoring Program, please contact us at [NCORP@wakehealth.edu](mailto:NCORP@wakehealth.edu)!**

## Top Accruing CC Affiliates\*

Rank	Affiliates	Accruals
1	IL042 - John H. Stroger Jr. Hospital of Cook County (Stroger MU)	3
2	SC058 - Tideland's Georgetown Memorial Hospital (MUSC MU)	2
	SC055 - Prisma Health Cancer Institute - Easley (Prisma Health)	
	PA052 - Geisinger Medical Center (Geisinger)	
	NJ141 - CentraState Medical Center (Atlantic Health)	
	IA074 - Mission Cancer and Blood - Laurel (IWORC)	
	IA072 - Mission Cancer and Blood - Des Moines (IWORC)	

\* Data from 01/01/2024 - 03/31/2024

## Top Accruing CCCR Affiliates\*

Rank	Affiliates	Accruals
1	IL042 - Stroger Jr. Hospital of Cook County (Stroger MU)	8
2	WI028 - Aspirus Regional Cancer Center (CROWN)	4
3	NY313 - Montefiore Med Ctr - Einstein Campus (Montefiore MU)	3
	IA004 - Iowa Methodist Medical Center (IWORC)	
4	MN014 - Park Nicollet Clinic - Saint Louis Park (MMCORC)	2

\* Data from 01/01/2024 - 03/31/2024

## Site Highlight: Iowa Oncology Research Association NCORP



Iowa-Wide Oncology Research Coalition (I-WORC) NCORP is a decentralized NCORP with the lead site located at Iowa Oncology Research Association in Des Moines. I-WORC NCORP has 25 CTEP sites across Iowa consisting of both clinical and hospital settings, with primary affiliate locations in Des Moines, Cedar Rapids, and Ames. Our catchment area encompasses 63 of Iowa's 99 counties. Currently, we have 111 rostered investigators to research including physicians, nurse practitioners, and physician assistants and 16 clinical research coordinators across the NCORP. In collaboration with our affiliated sites and utilizing a robust trial portfolio, we work together to reach all Iowa populations.

It is our mission to strive to provide excellence in cancer care to patients and families through participation in high quality cancer research studies including cancer control, prevention, treatment, and care delivery. I-WORC NCORP accrued 229 patients to NCI trials last year and anticipate exceeding last year's numbers. Our goal is to have 6% of our cancer patients participating in clinical trials. In 2023, we had over 9% of adult and pediatric patients enrolled in clinical trials.

Research-related facts about I-WORC NCORP:

- Wake Forest trials we have open include WF-2202 SHINE, WF-1805CD HN-STAR, WF-1806 M&M, and WF-1901 IMPACTS.
- We have enrolled 3 patients to the WF-2202 SHINE trial since it became active on February 29<sup>th</sup>.
- We screen every new patient to our oncology clinics for research trials.
- The population we serve is 40% rural and 60% urban, 49% female and 50% male.
- Our research base memberships: Alliance, ECOG-ACRIN, NRG, Wake Forest, COG, and URCC.
- We have 99 NCI trials open to accrual including individual cohorts and sub-studies. Our portfolio is a balance of cancer control trials, treatment trials, and cancer care delivery trials.
- We are 2<sup>nd</sup> highest in accrual for S2013 Immune Checkpoint Inhibitor Toxicity Trial.
- We are leading in accrual for the EAQ211 AYA study for survivors of Hodgkin and Non-Hodgkin Lymphoma.

---

*Do you have site or staff that should be recognized? Please submit recommendations to [NCORP@wakehealth.edu](mailto:NCORP@wakehealth.edu) with "Quarterly Newsletter Site/Staff Highlight" in the subject line.*

## **Top Accruing Investigators by Study**

(from 01/01/2024 - 03/31/2024)

### **WF-1805CD**

1. Sydney Spring, PA-C (8) - IL042, Stroger MU
2. Rafi Kabarriti, MD (4) - NY045, NY313, Montefiore MU

### **WF-1806**

1. Kumar Batra, MD (3) - IL042, Stroger MU
2. Patrick Kuhlman, MD (2) - SC055, Prisma Health
2. Mina Makary, MD (2) - PA052, Geisinger

### **WF-1901**

1. 13 Providers had 1 accrual

### **WF-2201**

1. Christina Cramer, MD (1) - NC002

### **WF-2202**

1. Kristel Howell, ARNP (3) - IA071, IA074

## **Top CC Accruing Investigators**

(from 01/01/2024 - 03/31/2024)



Kumar Batra, MD  
IL042, Stroger MU (3)



Kristel Howell, ARNP  
IA071, IA074, IWORC (3)

## **Top CCDR Accruing Investigators**

(from 01/01/2024 - 03/31/2024)



Sydney Spring, PA-C  
IL042, Stroger MU (8)



Rafi Kabarriti, MD NY045,  
NY313, Montefiore MU (4)



## Meet Wake Forest NCORP Research Base Staff: Tammy Vogler



Mrs. Tammy Vogler has been with the Wake Forest NCORP Research Base Team for 12 years. She started as a Research RN recruiting and following patients on our studies and transitioned to a site coordinator. She has been with our institution for 37 years with various experiences in the hospital and clinical settings in Nursing both Oncology and Cardiology, Adults and Pediatrics. She and her husband Mike live in a rural area north of Lexington, North Carolina. She has 2 grown sons, daughters in law and 3 grandchildren - granddaughter 4yrs old and 2 grandsons, 1yr and 1 month old. She stays busy playing with her grandchildren, taking care of her family, church, and going to the lake.

---

---

### New Publications & Presentations

#### Manuscripts:

- **REMEMBER WF-97116:** Rapp SR, Dressler EV, Brown MA, et al. Phase III randomized, placebo-controlled clinical trial of Donepezil for treatment of cognitive impairment in breast cancer survivors after adjuvant chemotherapy (WF-97116). *Journal of Clinical Oncology*. 2024.
- **UPBEAT WF-97415:** Garg R, D'Agostino Jr. RB, O'Connell N, et al. Hypertension severity and declines in left ventricular ejection fraction among women receiving adjuvant chemotherapy for breast cancer (WF-97415 UPBEAT). *Hypertension*. 2024.
- **Pilot Project:** Hughes RT, Levine BJ, Frizzell BA, et al. Keratin-based topical cream for radiation dermatitis during head and neck radiotherapy: a randomised, open-label pilot study. *Journal of Radiotherapy Practice*. 2024; 23(e11), 1–11

#### Abstracts:

- **OaSiS WF-20817CD:** Kittel CA, Dressler E, Snaveley A, Foley K. Reducing dimensionality of fidelity measurements in implementation science trials: A case example in equivalence between principal component and multiple correspondence analyses. *Society for Clinical Trials Annual Meeting*. 2024, May 19-22
- **SHINE WF-2202:** Shaffer KM, Reese J, Dressler EV, et al. Optimizing internet-based psychosocial intervention for breast cancer-related sexual morbidity: Protocol for a factorial trial. 2024 Scientific Network on Female Sexual Health and Cancer. 2024, April 18-19

## Health Equity Core Updates

In March of this year, our Health Equity Core leadership team made a site visit to the Hawai'i NCORP. They participated in clinic visits, meetings with several faculty and staff, performed some training and gave Grand Rounds.

Takeaways from this visit:

- Clinic champions are key
- APPS are important
- Space is very limited
- Interest in developing research
- Provider turnover

Training – there were approximately 35 attendees, consisting of advocates, research coordinators, outreach team, faculty, NCORP staff, and navigators.

Topics included:

- NCORP overview
- Health equity & research
- Research advocacy



Please let us know if your NCORP site would be interested in a visit!

---

The Wake Forest NCORP Research Base Health Equity Core focuses on recruitment & retention of minority/underserved populations. This group meets quarterly to share best practices, influence study design, discuss community engagement strategies and share resources and tools. If you are interested in joining this group, please contact us at [NCORP@wakehealth.edu](mailto:NCORP@wakehealth.edu)



## Wake Forest NCORP Research Base Annual Meeting

We hope to see you **October 21-23, 2024** at the Marriott Grande Dunes Resort in Myrtle Beach, SC!



### Travel Awards

We will be presenting travel awards to sites with the most enrollment to WF-1805CD HN-STAR, WF-1806 M&M, WF-1901 IMPACTS, WF-2201 HYPOGRYPHE, and WF-2202 SHINE **between February 1 and September 15, 2024**.

- Awards will be given to 2 sites for each study.
- Travel awards assist with travel to our 2024 Wake Forest NCORP RB Annual Meeting in Myrtle Beach, SC, October 21-23.
- **Awards are worth up to \$1,000 each** to cover travel and hotel expenses at The Grande Dunes Marriott Resort.

---

---

### WF NCORP RB Quarterly Calls

The next Quarterly call is scheduled for July 31, 2024. To view the recording from the last quarterly call (April 24, 2024) please click here: <https://vimeo.com/908663991>

# Spring Pesto Pasta

By: The Candid Appetite | Photographed by: Jonathan Melendez

## Salt and Pepper

1 pound curly-edged pasta, or any cut you prefer

## For Pesto:

3 tablespoons sliced almonds  
1 cup flat-leaf parsley  
½ cup fresh tarragon leaves  
½ cup fresh mint leaves  
3 cloves garlic

1 teaspoon lemon zest

¼ cup freshly grated Parmesan  
¼ cup extra-virgin olive oil

## For Cream Sauce:

2 tablespoons butter  
1 large shallot, finely chopped  
1 (10 ounce) box frozen peas  
½ cup white wine or chicken stock  
1 cup heavy cream

1. Bring a large pot of water to a boil, salt it and add the pasta. Cook to al dente; drain and reserve a cup of the cooking liquid for later.
2. While the pasta is cooking, add all the pesto ingredients into a food processor or blender, pulse into a thick paste.
3. Melt the butter in a large skillet over medium heat. Add the shallot and stir for a couple of minutes. Add the peas and stir to heat through. Stir in the wine (or stock) and cook to reduce, 2 to 3 minutes. Add the cream and season with salt and pepper to taste. Lower the heat and let the sauce thicken a bit.
4. Toss the pasta with the cream sauce and the pesto. Add a bit of the reserved pasta water to loosen the sauce, if desired. Sprinkle with more parmesan cheese. Enjoy!

For more simple and delicious recipes please visit [www.thecandidappetite.com](http://www.thecandidappetite.com)

**NCI** Community Oncology  
Research Program

A program of the National Cancer Institute  
of the National Institutes of Health

Copyright © 2024 Wake Forest NCORP Research Base, All rights reserved.  
You were added to this email list when you were rostered to the WAKE NCORP Research Base

### Our mailing address is:

Wake Forest NCORP Research Base  
Medical Center Blvd  
Winston Salem, NC 27157-0001

[Add us to your address book](#)

Want to change how you receive these emails?  
You can [update your preferences](#) or [unsubscribe from this list](#).

